Abstract:Background The ocular features of phacomatosis pigmentovascularis (PPV) have rarely been reported, and glaucoma is the leading cause of blindness in patients with this condition. To protect vision in these patients, it is important to identify glaucoma as early as possible. Objectives To systematically report the systemic and ocular manifestations of phacomatosis cesioflammea and phacomatosis cesioflammeo-marmorata, and to investigate a glaucoma risk scoring system. Materials & Methods In this prospective study, patients with PPV from 2014 to 2021 were included. Clinical information was collected, and associations with glaucoma were evaluated. The suitability of the scoring system was assessed. A systematic literature review and analysis of reported cases of PPV was performed. Results A total of 28 participants with PPV were included. Their ocular findings were similar, ranging from episcleral hyperpigmentation (78.5%), glaucoma (75%), choroid haemangioma (38%), and retinal vascular abnormalities (48%), to hyperpigmentation of the cornea, iris, lens and fundus. Glaucoma was associated with multiple factors, especially a thick choroid (odds ratio: 2.61; p = 0.008) and a diffuse mass-type of episcleral hyperpigmentation (odds ratio: 41.3; p = 0.027). The risk scoring system was characterized by high sensitivity (84%) and specificity (80%; AUC = 0.91) in predicting glaucoma. Conclusion In addition to involving the systemic system, phacomatosis cesioflammea and phacomatosis cesioflammeomarmorata also represent a specific spectrum of ophthalmic vascular malformations and hyperpigmentation. Early and periodic detailed ocular examination are recommended. The novel scoring system will help to tailor follow-up for visual protection.

The research progress in diagnosis and treatment of phakomatosis pigmentovascularis

Ocular manifestations and advances of phacomatosis pigmentovascularis

Clinical Analysis of 10 Cases of Children Phakomatosis Pigmentovascularis

Recent Advance on Pathogenesis of Choroidal Neovascularization

Birthmarks: Phacomatosis Pigmentovascularis

Advances in the Diagnosis and Treatment for Ocular Complication on Mucopolysaccharidosis

The development of hemangioma and vascular malformation (2020—2021)

Progress in the treatment of ocular neovascular diseases

[Clinical and imaging features of pulmonary veno-occlusive disease and pulmonary capillary hemangioma].

The Risk of Glaucoma Associated with Phacomatosis Cesioflammea and Phacomatosis Cesioflammeo-Marmorata

Progress in evidence-based research on the clinical treatment of infantile hemangioma and vascular malforma-tions

Recent advances in the diagnosis and treatment of Coats’ disease

Hematoporphyrin monomethyl ether-mediated photodynamic therapy temporarily relieves severe pruritis from phakomatosis pigmentovascularis: A case report

The development of the diagnosis and treatment of parafoveal telangiectasis

Current Trends in Clinical Characteristics, Diagnosis, and Treatment of Polypoidal Choroidal Vasculopathy: A Perspective from Vietnam

Retinitis Pigmentosa: Progress and Perspective

Progress in the Treatment of Venous Malformations

Research progress in peripapillary atrophy

Progress in clinical research and applications of retinal vessel quantification technology based on fundus imaging

[Research progress of persistent hyperplastic primary vitreous with Peters anomaly]

Progress in research on pathogenic genes and gene therapy for inherited retinal diseases